Why the study?
The clinical impact of heart failure on postoperative outcomes following video-assisted thoracic surgery for lung cancer resection remained controversial.
Does the presence of heart failure worsen postoperative outcomes in lung cancer patients undergoing VATS lobectomy or sublobar resection?
Does the presence of heart failure worsen postoperative outcomes in lung cancer patients undergoing VATS lobectomy or sublobar resection?
The presence of heart failure significantly increases in-hospital mortality, length of stay, costs, and complications in lung cancer patients undergoing VATS resection.
Answers are grounded in this paper and cite their sources.
HF warrants heightened perioperative vigilance in lung cancer resection; observational data leaves open whether targeted interventions improve outcomes.
Background: The clinical impact of heart failure (HF) on postoperative outcomes following video-assisted thoracic surgery (VATS) for lung cancer resection remains controversial. This study aimed to assess patient and hospital characteristics related to the type of surgery, as well as the independent impact of HF on surgical outcomes. Methods: We conducted a retrospective analysis using data from the National Inpatient Sample database. A total of 20 693 patients aged 18 years or older, diagnosed with lung cancer, and undergoing lobectomy or sublobar resection via VATS between 2016 and 2020 were included. Patients were stratified based on the presence of HF. The HF-present cohorts were matched to HF-absent controls using a 1:2 nearest-neighbor propensity score-matching (PSM) analysis. The matched cohorts were then compared across several endpoints, including mortality, length of stay (LOS), hospitalization costs, and postoperative complications. Results: After PSM, the study included 1781 patients who underwent lobectomy and 1157 who underwent sublobar resection, with 594 and 386 patients, respectively, having concurrent HF. In both the lobectomy and sublobar resection groups, patients with HF demonstrated significantly higher in-hospital mortality rates ( P < .001), longer LOS ( P < .001), increased total hospital charges ( P < .001), and a greater risk for overall postoperative complications ( P < .001). Conclusions: Among patients with lung cancer undergoing VATS, the presence of HF is associated with an increased risk of postoperative complications. This finding underscores the necessity for enhanced monitoring and care for patients with HF should be treated during the postoperative recovery phase.
No takes yet. Share an insight, caveat, or question.
He et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: